An interventional study of To explore the value of spectral CT in the diagnosis and treatment of liver cancer in Liver Cancer, sponsored by Yunnan Cancer Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Yunnan Cancer Hospital · Not applicable, Interventional, and Diagnostic
Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.
This study's planned enrollment of 150 is above the median of 47 across 968 interventional studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →Yunnan Cancer Hospital is the lead sponsor of 28 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Prospectively collect medical images and clinical data related to liver cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of liver cancer.Patients diagnosed with liver cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of liver cancer patients was assessed by two radiologists, and finally statistical analysis was performed.
Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of liver cancer
The CT scan is part of the standard treatment protocol.
Pathological TNM staging
Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Time frame: 1 day
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yunnan Cancer Hospital